Oncopeptides AB

Oncopeptides AB
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

Oncopeptides is a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company uses its proprietary peptide-drug conjugate (PDC) platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. The first drug coming from PDC platform, PEPAXTO®(melphalan flufenamide), has been launched in the U.S., for the treatment of adult patients with relapsed or refractory multiple myeloma. Melphalan flufenamide is evaluated in a comprehensive clinical study program including the global phase 3 studies OCEAN and LIGHTHOUSE. Oncopeptides is developing several new compounds based on the PDC platform. The first one is expected to enter into clinical development in 2021.Oncopeptides has approximately 300 coworkers. The global Headquarters is based in Stockholm, Sweden and the U.S. Headquarters is situated in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. More information is available on www.oncopeptides.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Oncopeptides presents phase 3 OCEAN study results at the IMW meeting

Sat, Sep 11, 2021 10:15 CET

STOCKHOLM — September 11, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today presents data from the phase 3 OCEAN study, a direct head to head comparison of the efficacy and safety of melflufen (INN melphalan flufenamide) plus dexamethasone and pomalidomide plus dexamethasone in patients with relapsed refractory multiple myeloma, (RRMM), who are refractory to lenalidomide and have received 2-4 prior lines of therapy. The data was presented today by Fredrik Schjesvold,

Invitation to webcast for presentation of OCEAN data presented at IMW

Thu, Sep 09, 2021 16:49 CET

STOCKHOLM — September 9, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, will present data from the OCEAN study at the 18th International Myeloma Workshop (IMW) on September 11. Investors, financial analysts, and media are invited to participate in a webcast including a Q&A on September 12 at 16:00 CEST. The event will be hosted by CEO, Marty J Duvall, Klaas Bakker, CMO as well as Fredrik Schjesvold, MD, Head of Oslo Myeloma Center. The presentation will be held in English.

Oncopeptides presents new data from OCEAN and PORT study - abstracts online

Fri, Aug 27, 2021 19:30 CET

STOCKHOLM — August 27, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that data from the phase 3 OCEAN study has been accepted as an oral presentation at the upcoming 18[th] International Myeloma Workshop (IMW), and the abstract is now available online. More comprehensive data will be presented at the IMW-meeting in Vienna on September 11, at 10:00 (CET).The phase 3 OCEAN study is a head-to-head comparison evaluating the efficacy and safety of melflufen (

New Interim Data in RRMM Patients with Extramedullary Disease from the Pivotal Phase 2 Horizon-study presented at International Myeloma Workshop

Sun, Sep 15, 2019 14:30 CET

Stockholm – September 15, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today updated interim efficacy and safety data from the ongoing pivotal Phase 2 study, HORIZON, at the 17th International Myeloma Workshop (IMW) meeting in Boston, Massachusetts, USA. The data focused on patients with extramedullary disease (EMD) and was presented in an oral presentation by Professor Paul G. Richardson. Oncopeptides will host a conference call to review this data on Monday, September 16, 2019, at. 08.30 (CET).The results presented at IMW 2019 by Professor Paul G Richardson in the plenary

Oncopeptides Announces Two Poster Presentations at the International Myeloma Workshop

Sat, Sep 14, 2019 13:00 CET

Stockholm – September 14, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that our two poster presentations have been made public at the 17th International Myeloma Workshop (IMW) meeting in Boston, Massachusetts, USA.The posters presented at IMWThe first poster presentation was held during Poster Session I, Multiple Myeloma Genomics – under the title: Aminopeptidase gene expression in myeloma. The second poster presentation was held during Poster Session II, Treatment of Previously Treated Myeloma –under the title: Quality of life treatment for relapsed/refractory

New updated data will be presented from Oncopeptides’ Pivotal Phase 2 HORIZON study in patients with extra medullary disease (EMD) on September 15th

Fri, Aug 30, 2019 08:15 CET

Stockholm - 30 August 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that new updated melflufen data from the Phase 2 pivotal OP-106 HORIZON study will be presented at at the 17th International Myeloma Workshop (IMW) meeting on September 15, Boston, Massachusetts, USA. These data are from at later data cut compared with previously presented data at EHA in June or in the abstract book for IMW.In conjuction with the presentation the new data will be available on the company webpage under: www.oncopeptides.com /

Oncopeptides Announces Acceptance of Data for Presentation at International Myeloma Workshop, September 12-15

Fri, Aug 16, 2019 22:00 CET

Stockholm – August 16, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today the acceptance of an oral late breaking presentation providing updated melflufen data from the Phase 2 pivotal OP-106 HORIZON study as well as two poster presentations at the 17th International Myeloma Workshop (IMW) meeting (September 12-15, Boston, Massachusetts, USA). Melflufen is a lipophilic peptide-conjugated alkylator belonging to a novel class of Peptidase Enhanced Cytotoxics (PEnC) and is presently being evaluated in a broad global clinical development program.Comment from CEO Jakob Lindberg“

There are no items matching the current filter

There are no more items matching the current filter

Share